AIM ImmunoTech Inc (AIM)
0.2505
-0.01
(-4.06%)
USD |
NYAM |
Nov 04, 13:10
AIM ImmunoTech Revenue (Quarterly): 0.05M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.05M |
| March 31, 2024 | 0.04M |
| December 31, 2023 | 0.065M |
| September 30, 2023 | 0.046M |
| June 30, 2023 | 0.042M |
| March 31, 2023 | 0.049M |
| December 31, 2022 | 0.056M |
| September 30, 2022 | 0.021M |
| June 30, 2022 | 0.03M |
| March 31, 2022 | 0.033M |
| December 31, 2021 | 0.05M |
| September 30, 2021 | 0.033M |
| June 30, 2021 | 0.023M |
| March 31, 2021 | 0.028M |
| December 31, 2020 | 0.042M |
| September 30, 2020 | 0.036M |
| June 30, 2020 | 0.04M |
| March 31, 2020 | 0.045M |
| December 31, 2019 | 0.05M |
| September 30, 2019 | 0.061M |
| June 30, 2019 | 0.029M |
| March 31, 2019 | |
| December 31, 2018 | 0.24M |
| September 30, 2018 | 0.038M |
| June 30, 2018 | 0.033M |
| Date | Value |
|---|---|
| March 31, 2018 | 0.056M |
| December 31, 2017 | 0.05M |
| September 30, 2017 | 0.09M |
| June 30, 2017 | 0.213M |
| March 31, 2017 | 0.084M |
| December 31, 2016 | 0.016M |
| September 30, 2016 | 0.022M |
| June 30, 2016 | 0.015M |
| March 31, 2016 | 0.039M |
| December 31, 2015 | 0.027M |
| September 30, 2015 | 0.023M |
| June 30, 2015 | 0.047M |
| March 31, 2015 | 0.036M |
| December 31, 2014 | 0.04M |
| September 30, 2014 | 0.045M |
| June 30, 2014 | 0.036M |
| March 31, 2014 | 0.076M |
| December 31, 2013 | 0.036M |
| September 30, 2013 | 0.036M |
| June 30, 2013 | 0.036M |
| March 31, 2013 | 0.042M |
| December 31, 2012 | 0.053M |
| September 30, 2012 | 0.039M |
| June 30, 2012 | 0.049M |
| March 31, 2012 | 0.072M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.021M
Minimum
Sep 2022
0.065M
Maximum
Dec 2023
0.041M
Average
0.042M
Median
Dec 2020
Revenue (Quarterly) Benchmarks
| Perspective Therapeutics Inc | -- |
| Protalix BioTherapeutics Inc | 13.47M |
| Electromed Inc | 14.83M |
| Xtant Medical Holdings Inc | 29.94M |
| Armata Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -1.836M |
| Total Expenses (Quarterly) | 3.744M |
| EPS Diluted (Quarterly) | -0.03 |
| Enterprise Value | 9.109M |
| Gross Profit Margin (Quarterly) | 84.00% |
| Profit Margin (Quarterly) | -3.67K% |
| Earnings Yield | -227.5% |
| Normalized Earnings Yield | -223.77 |